Daily Morning Note – 8 December 2021

Welcome to our Daily Morning Note from our Research team!

Dear Valued Investors, Please note that our last Morning Note for 2021 will be on 13 December 2021.


Wall Street stocks rallied for a second straight session Tuesday as investors cheered early indications that the latest Covid-19 variant may be less severe than earlier rounds. The tech-rich Nasdaq Composite Index, which lagged other major indices Monday, led with a three per cent jump to 15,686.92. The Dow Jones Industrial Average climbed 1.4 per cent to 35,719.43, while the broad-based S&P 500 gained 2.1 per cent to 4,686.75. After worries about the Omicron variant pushed major indices into the red last week, stocks have been on the rise this week as fears of a worst-case scenario ebb. Top US scientist Anthony Fauci told AFP that while Omicron is highly contagious, “it almost certainly is not more severe than Delta.”



Yangzijiang Shipbuilding (Holdings) YZJ plans to spin off its investment segment in a listing on the Singapore Exchange mainboard, the board said in an update on Tuesday (Dec 7). If the spin-off and listing are successful, the plan is for Yangzijiang shareholders to get shares of the spin-off group proportionally, through dividend in specie. The company had announced on Nov 29 that the group was looking into transferring investments to a spin-off group that would focus on asset management and direct investments.

QT Vascular is staring down a possible do-over of a recent extraordinary general meeting (EGM), said its board in an update released on Tuesday (Dec 7). The board said it got an e-mail on Monday afternoon from would-be director Christian Kwok-Leun Yau Heilesen, seeking a fresh vote on the resolutions that had failed to pass muster that very morning. Requisitioning shareholders Mission Well Ltd and Tansri Saridju Benui had last month called for an EGM for shareholders to decide on appointing Tansri, Mission Well director Heilesen, and 3 others to the board. The 5 resolutions were rejected at the EGM on Monday.

Viking Offshore & Marine has named Xandar Capital as the independent financial adviser in an ongoing offer exercise for the company’s shares. The advice of the independent financial adviser and the recommendation of the independent directors will be sent to shareholders within 14 days of Dec 6, the board said on Tuesday (Dec 7). It has also appointed Lee & Lee as solicitors to act for the company over the offer.


Intel Corp is planning to publicly list shares in its self-driving-car unit Mobileye, the Wall Street Journal reported on Monday, citing people familiar with the matter. However, there are no guarantees Intel will ultimately follow through with an offering, the report said, adding that the announcement is expected as soon as this week.

American Airlines Group named President Robert Isom to replace Doug Parker as chief executive officer early next year, a sign of stability after the Covid-19 pandemic ignited a chaotic period for the industry. Parker, who has led the airline since 2013, will step down as CEO on March 31 but stay on as chairman, according to a statement Tuesday.

Google said Tuesday it has moved to shut down a network of about one million highjacked electronic devices used worldwide to commit online crimes, while also suing Russia-based hackers the tech giant claimed were responsible. The so-called botnet of infected devices, which was also used to surreptitiously mine bitcoin, was cut off at least for now from the people wielding it on the internet.

US President Joe Biden and Russian President Vladimir Putin began virtual talks on Ukraine and other disputes on Tuesday, Russian state TV reported, amid Western fears that Moscow is poised to invade its southern neighbour. Russian TV footage showed Biden and Putin greeting each other in a friendly manner at the start of what was expected to be a tense exchange. Biden told Putin he hoped their next meeting would be in person.

The United States slapped fresh sanctions on a dozen Iranian officials and entities for “serious” human rights abuses on Tuesday, ahead of the expected resumption of nuclear talks with Tehran after they halted last week without any concrete progress.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

Technical Pulse: SPDR S&P Biotech ETF

Recommended: Technical BUY; Analyst: Chua Wei Ren

SPDR S&P Biotech ETF (US: XBI) Technical price action indicates a potential upside after a prolonged downtrend since February 2020

Buy stop: 116.70 Stop loss: 106.54 Take profit 1: 132.00 Take profit 2: 145.00

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Daily Morning Note – December 3, 2021

Daily Morning Note – December 2, 2021

LHN limited – SGX Company Insights Ep 44

Visit www.stocksbnb.com to learn more!

Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click here to join: https://t.me/stocksbnb

Webinar Of The Week

Weekly Market Outlook: MUST, Digital Core REIT, LHN, Marco Polo Marine, Marathon Digital, SG Weekly.

Date: 6 December 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com